Myelodysplastic Syndrome — Research Summary
Printed from RareWays (rareways.com.au) on 10 September 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Association between red cell distribution width to albumin ratio and all-cause mortality in critically ill patients with myelodysplastic syndrome: a retrospective cohort study.
Huang Zicong et al. — Hematology (Amsterdam, Netherlands) (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41841600/
- 2.
Rabdosin B suppresses proliferation of nonsmall cell lung cancer by regulating the SRC/PI3K/AKT signaling pathway.
Chen Xinfei et al. — Pharmaceutical biology (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41858068/
- 3.
Poor sleep quality correlates with axial symptoms and mood problems in Parkinson's disease.
Taniguchi Seira et al. — Dialogues in clinical neuroscience (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42290512/
- 4.
Engineered decellularized muscle extracellular matrix fabrics enable functional volumetric muscle loss repair.
Song Guangzhou et al. — Bioactive materials (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42306336/
- 5.
Clinical characteristics and predictors of disease progression in parkinson's disease in a cohort of patients in the ashanti region, Ghana.
Obese Vida et al. — Equity neuroscience (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42245155/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Recruiting — Phase 3 — Takeda
https://clinicaltrials.gov/study/NCT07422480
- 2.
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Recruiting — Phase 1 — AstraZeneca
https://clinicaltrials.gov/study/NCT07155226
- 3.
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Recruiting — Phase 3 — Takeda
https://clinicaltrials.gov/study/NCT06499285
- 4.
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Recruiting — Phase 1 — Beijing InnoCare Pharma Tech Co., Ltd.
https://clinicaltrials.gov/study/NCT06656494
- 5.
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Recruiting — Phase 3 — Institut de Recherches Internationales Servier
https://clinicaltrials.gov/study/NCT06465953
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Myelodysplastic Syndrome
Myelodysplastic Syndrome encompasses a group of blood cancers in which the bone marrow produces abnormal, dysfunctional blood cells. The condition predominantly affects older adults and can progress to acute myeloid leukaemia. Treatment ranges from supportive care and growth factors to stem cell transplantation in eligible patients.
Most Recent Research
BACKGROUND: The red cell distribution width to albumin ratio (RAR) has emerged as a novel, easily calculated biomarker demonstrating prognostic value across various diseases. However, the relationship of RAR for all-cause mortality risk in critically ill patients with myelodysplastic syndromes (MDS) remains unclear. OBJECTIVES: To explore the association between RAR and all-cause mortality in critically ill patients with MDS. METHODS: This retrospective cohort study utilized patient data from the MIMIC-IV database. The study population was patients with MDS admitted to ICU for the first time. The main outcome was all-cause mortality at 28-day, 90-day, and 365-day. The association between RAR and all-cause mortality was evaluated using Cox proportional hazards regression analysis. Restricted Cubic Spline (RCS) regression was employed to test for any non-linear relationship between RAR levels and the mortality risk. RESULTS: Patients in the high RAR group showed significantly worse survival rates across time points of 28-day, 90-day, and 365-day compared to the low RAR group (log-rank test, all P < 0.001). In the adjusted multivariable Cox regression model, elevated RAR as a continuous variable was significantly associated with an increased risk of all-cause mortality: 28-day (HR = 1.18; 95% CI: 1.08-1.29; P < 0.001), 90-day (HR = 1.18; 95% CI: 1.09-1.27; P < 0.001), and 365-day (HR = 1.17; 95% CI: 1.10-1.25; P < 0.001). RCS analysis confirmed a positive but non-linear association between increasing RAR levels and heightened mortality risk. CONCLUSIONS: RAR, a readily available composite biomarker, is associated with all-cause mortality in critically ill patients with MDS.
Common Questions
What is Myelodysplastic Syndrome?
Myelodysplastic Syndrome encompasses a group of blood cancers in which the bone marrow produces abnormal, dysfunctional blood cells. The condition predominantly affects older adults and can progress to acute myeloid leukaemia. Treatment ranges from supportive care and growth factors to stem cell transplantation in eligible patients.
How many clinical trials are available for Myelodysplastic Syndrome?
RareWays currently indexes 1691 clinical trials for Myelodysplastic Syndrome, of which 323 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Myelodysplastic Syndrome come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Myelodysplastic Syndrome.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.